The pharmacokinetics of AM-833 [6, .4-oxo-3-quinolinecarboxylic acid] were studied in mice, rats, rabbits, dogs, and monkeys by reversed-phase high-performance liquid chromatography. AM-833 was rapidly and completely absorbed from the digestive tracts of mice, rats, and dogs. About half of AM-833 bound to rat and dog serum proteins. Drug levels in lung, spleen, liver, and kidney tissues of rats and dogs were greater than the respective levels in serum but lower in brain tissue. Drug levels in tissues declined with the decrease in levels in serum. AM-833 penetrated rapidly and well into inflammatory exudate of rats. Elimination half-lives in serum were species dependent, ranging from 1.57 h in rabbits to 9.42 h in dogs. Profiles of drug levels in serum were dose related over a single dose range from 2 to 40 mg/kg and not modified significantly during multiple dosing in dogs. Unchanged AM-833 was excreted in urine and bile in both rats and dogs. The metabolism of AM-833 was suggested by evidence that 24-h total recovery of unchanged AM-833 in urine and bile accounted for about half of the intravenous dose in rats.
6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid (AM-833) is a new pyridonecarboxylic acid derivative ( Fig. 1 ) with potent and broad in vitro antibacterial activity against gram-positive and gram-negative bacteria (1) . The compound also exhibited significant activity against various experimental infections (1) . This paper describes the absorption, distribution, and excretion of AM-833 in various experimental animals.
( 830530 ) and an internal standard (1-ethyl-6-fluoro-1,4-dihydro-7-imidazol-1-yl-4-oxo-3-quinolinecarboxylic acid) for analysis were synthesized in our laboratories. All other reagents were of analytical grade.
Animals. Male ICR mice (body weight, about 30 g), male Wistar rats (250 to 450 g), male Japanese White rabbits (3.1 to 3.5 kg), male and female beagle dogs (8.5 to 13.0 kg), male mongrel dogs (8.5 and 11.0 kg), and male cynomolgus monkeys (5.0 to 5.7 kg) were treated. Unless otherwise stated, male beagle dogs were used.
Drug administration. AM-833 was administered to fasting animals except when repeatedly given to dogs. A suspension for oral administration was prepared by homogenizing the powder in 0.3 to 0.5% carboxymethyl cellulose sodium aqueous solution. An aqueous solution for intravenous and oral administration was prepared by dissolving AM-833 in 0.1 N sodium hydroxide and then adjusting the pH to 9 to 10 with 2 N hydrochloric acid in which osmolarity was maintained at physiological pressure by addition of sodium chloride. Single oral doses were given to 30 mice (10 or 50 mg/kg) * 6 dogs (2 or 10 mg/kg by foreleg vein), and 3 monkeys (10 mg/kg by leg vein) by direct injection and to 4 rats (10 mg/kg) through a polyethylene catheter inserted into the femoral vein. For determination of levels in tissues, AM-833 was given to five rats as a bolus injection (3.90 mg/kg) and then infused at a rate of 1.05 mg/kg per h for 2 h, and AM-833 was given to three female beagle dogs as a bolus injection (6.84 mg/kg) and then infused at a rate of 0.50 mg/kg per h for 3.5 h through a polyethylene catheter introduced into the femoral and foreleg veins, respectively. In an experiment on urinary and biliary excretion in dogs, the aqueous solution (10 mg/kg) was intravenously given to two male mongrel dogs via a polyethylene catheter inserted into the foreleg vein. Ringer solution containing 0.8% (wt/vol) glucose was intravenously given dropwise at a rate of 40 ml/h during collection of urine and bile samples. In four rats AM-833 (10 mg/kg) was intravenously injected through a polyethylene catheter inserted into the femoral vein for collection of urine and bile. The granuloma pouches of rats were prepared by the Selye procedure (7). Acute exudative inflammation was induced by injecting 1 ml of olive oil containing croton oil (1%) into an air pouch which had been produced by introducing 20 ml of air into subcutaneous tissue on the dorsa of rats; the air was removed 3 days later. AM-833 (10 mg/kg) was intravenously injected into four rats on day 6 of inflammation.
Preparation of assay specimens. Mouse (Kinematica, GmbH) . The homogenate was centrifuged at 2,000 x g for 20 min to separate the supernatant. Urine and bile samples of rats were collected through polyethylene catheters inserted into the bladders and common bile ducts, respectively, for 0 to 3, 3 to 6, and 6 to 24 h. Blood, urine, and bile samples of mongrel dogs were taken through polyethylene catheters inserted into the femoral veins, left and right ureters, and common bile ducts, respectively. Blood was taken at 1, 3, 5, 7, 9, 11, 16, and 20 h; urine and bile were collected at 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 10, 10 to 12, 12 to 16, and 16 to 20 h. Granuloma exudate and blood of rats were taken through needles for injection from dorsal pouches at 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h. All specimens were stored at -20°C until analyzed.
Protein binding. In vivo protein binding of AM-833 was examined by the ultrafiltration method. From 10 rats given AM-833 orally blood samples were taken at 0.5, 1, 2, 4, and 8 h after dosing, and from five dogs given 100 mg each orally blood was taken at 0.25, 0.5, 0.75, 1, 2, and 6 h after dosing. Serum was separated by centrifugation at room temperature. Portions (5 ml) of serum were loaded on an Amicon Centriflo CF-25 membrane. The concentrations in serum and ultrafiltrate were regarded as the total and unbound concentrations, respectively. The extent of adsorption of AM-833 to the membrane was determined by using 1/15 M phosphate buffer (pH 7.4) containing AM-833 in a range from 0.1 to 8 ,ug/ml. The binding rate was corrected with the extent of adsorption (8%). A sample of a biological specimen (0.1 to 1 ml) was mixed with 0.1 ml of an internal standard solution, 1 ml of 0.5 M phosphate buffer (pH 7.5), and 6 ml of chloroform. The internal standard solution was prepared by dissolving 1-ethyl-6-fluoro-1,4-dihydro-7-imidazol-1-yl-4-oxo-3-quinolinecarboxylic acid in 0.02 N sodium hydroxide (30 to 150 ,ug/ml). The resulting mixture was vigorously shaken for S min and centrifuged at 2,000 x g for 5 min, and 5 ml of the chloroform layer was removed and evaporated. The resulting residue was dissolved in 0. was the half-life calculated from the elimination rate constant determined by linear regression analysis. AUCo was the area under the curve (AUC) calculated as the sum of AUC obtained from zero to the last time by the trapezoidal rule and the ratio of the last concentration measured to the elimination rate constant in the terminal phase. Concentrations in serum during repeated dosing were simulated by using a multiple-dose kinetic equation with a first-order absorption and elimination rate constant based on the onecompartment model. RESULTS Levels in serum. Profiles of AM-833 levels in the sera of mice, rats, rabbits, dogs, and monkeys given a single intravenous dose (10 mg/kg) are illustrated in Fig. 3 . These animals exhibited a relatively wide species difference in elimination rates (Table 1) distribution of AM-833 in the body. In mice, rats, and dogs, levels of AM-833 in serum after an intravenous dose were compared with those after an oral dose (Fig. 4) (Fig. 5 ) when 2 mg/kg was given twice a day. The level in serum of 2.57 + 0.17 ,ug/ml at 2 h after the third dose was 1.54 times higher than the concentration after the corresponding first dose (1.67 ± 0.13 ,ug/ml) and about equal to that after the ninth dose (2.35 ± 0.12 1xg/ml). The respective minimal concentrations on days 2, 3, 4, and 5 were measured as 1.06 ± 0.10, 1.30 ± 0.16, 0.89 ± 0.09, and 0.91 ± 0.09 ,ug/ml. These values were fairly constant over the experimental period. The solid line in Fig. 5 Distribution. From 41 to 57% of AM-833 was bound in rat serum and 41 to 61% was bound in dog serum at total concentrations ranging from 1 to 7 ,ug/ml. The binding rate was about half of the total AM-833 and virtually independent of AM-833 concentration in the range studied. The mean levels of AM-833 in serum and pouch fluid when AM-833 was intravenously injected at a dose of 10 mg/kg into rats with granuloma pouches are present in Fig. 6 . The levels in serum decreased to 3.31 ± 0.28 and 0.36 ± 0.03 ,ug/ml at 2 and 8 h postadministration, respectively. The levels in pouch fluid reached peaks of 2.12 ± 0.09 ,ug/ml at 4 h postadministration and then decreased more gradually with a half-life of 6.38 h, resulting in levels in pouch fluid four times higher than levels in serum at 8 h postadministration. The mean penetration ratio to pouch fluid (AUCpouch fluid/ AUCserum) was 1.18.
AM-833 levels in brain, lung, liver, spleen, and kidney tissues of rats were measured both at the end of infusion and at 6 h postinfusion. The levels in lung, liver, spleen, and kidney tissues of dogs were determined at the end of constant infusion. Rats showed tissue/serum distribution ratios of 4.2 ± 0.2, 3.1 ± 0.1, 2.3 ± 0.1, 1.1 ± 0.1, and 0.17 ± 0.0 in kidney, liver, spleen, lung, and brain tissues, respectively, at the end of infusion. The respective ratios at 6 h postinfusion were 4.1 ± 0.2, 3.3 ± 0.1, 2.9 ± 0.1, 1.2 ± 0.1, and 0.25 ± 0.02. The distribution ratios in dogs were 3.5 ± 0.0, 2.8 + 0.2, 2.1 ± 0.1, and 1.6 ± 0.2 in liver, spleen, kidney, and lung tissues, respectively. These results indicate that AM-833 is well distributed among various tissues, but not in brain, and is eliminated from the tissues at rates similar to that of elimination from serum, because there were no significant changes in distribution ratio with time.
Excretion. Excretion of AM-833 urine and bile was examined in rats given a single intravenous or oral dose of 10 mg/kg ( Table 3 ). The peak levels of AM-833 were 430 + 143 and 310 ± 95 ,ug/ml in 0-to 3-h pooled urine after intravenous and oral administrations, respectively. The corresponding levels in bile were 46.1 + 10.2 and 45.5 + 4.1 ,ug/ml. The levels in 6-to 24-h pooled urine samples were 120 ± 20 and 115 + 21 ,ug/ml after intravenous and oral administration, respectively. The corresponding levels in bile were 24.1 ± 4.4 and 11.0 ± 2.1 ,ug/ml. The recovery of AM-833 in urine at 24 h postadministration was 42.9 + 6.8 and 36.2 ± 5.2% of the dose after intravenous and oral administrations, respectively. The respective percentages found in bile were 6.8 ± 1.9 and 5.7 ± 1.2%. Thus, 49.7 and 41.9% of the dose was totally excreted into both urine and bile in 24 h as unchanged .
The levels of AM-833 in serum, urine, and bile were determined in two mongrel dogs given a single intravenous dose of 10 mg/kg (Fig. 7) . In this experiment, the dogs were catheterized for collection of urine and bile. The elimination half-lives were 6.06 and 6.40 h, which were shorter than those of intact dogs ( Table 1) . The levels of AM-833 in urine of dogs were 410 and 548 ,ug/ml at 0 to 2 h postadministration and about 100 jig/ml at 12 h postadministration. The levels of AM-833 in bile of dogs were 370 and 231 jig/ml at 0 to 2 h postadministration and about 100 ,ug/ml at 12 h postadministration. Excretion percentages in urine and bile of dogs were 16.0 to 22.7 and 5.3 to 5.7% of the dose, respectively, at 16 h. These results indicated that biliary excretion contributed more to total excretion in dogs than in rats. (6, 8) but higher than those of other pyridonecarboxylic acid derivatives (2) (3) (4) (5) 9) . In experimental animals, precise bioavailability data of other derivatives are not available, but AM-833 exhibited almost perfect systemic availability in mice, rats, and dogs. Good availability of crystalline AM-833 administered orally was also confirmed in dogs. The present study revealed a large interspecies difference in the elimination half-life of AM-833 in mice, rats, rabbits, monkeys, and dogs. Rabbits had the shortest half-life (1.57 h), and dogs exhibited the longest half-life (9.42 h). Animals larger in body weight tended to show a longer half-life of AM-833, but rabbits showed exceptionally rapid elimination of AM-833, suggesting extensive metabolism in rabbits (H. Kusajima, T. Ooie, F. Kawahara, and H. Uchida, J. Chromatogr., in press). AM-833 exhibited elimination rates similar to those of pefloxacin (2) and enoxacin (4, 5, 9) slightly slower. Levels in serum during repeated dosing of dogs were well described by the multiple-dose pharmacokinetic equation, and the elimination half-life after the last dose was not significantly changed from that after the first dose. This evidence suggests no accumulation of AM-833 in rats and dogs.
The 24-h recovery percentages of unchanged AM-833 in urine and bile were 42.9 and 6.8% of the dose, respectively, 
